This field is in exponential growth as it is in close relationship with new targeted therapy approaches; adhesion molecules, extracellular-domain of epidermal growth factor receptor (ErbB 1) or Erb2 (HER2/neu), anti-p53 antibodies, belong to the functional tumour marker category. This evidence concerns the gene ERBB2 and neoplasm.